David M. Polen
Polen Capital Management
Polen Capital Management Arrowhead Pharmaceuticals Inc stake
total: 588
Polen Capital Management ARWR trades
- Total transactions:
- 1
- New positions:
- 1
- Held since:
- 2026 Q2
- Held for:
- 1 quarter
- Latest activity:
- 2026 Q2
According to 2026 Q2 report, Polen Capital Management holds 6,612 Arrowhead Pharmaceuticals Inc (ARWR) shares with a market value of roughly $538.94K accounting for 0.00% of the overall portfolio. To date, the estimated cost basis is nearly $81.51 for "buy" trades. Polen Capital Management first purchased ARWR in 2026 Q2, initially acquiring 6,612 shares.
When did Polen Capital Management buy Arrowhead Pharmaceuticals Inc (ARWR)?
Polen Capital Management first invested in Arrowhead Pharmaceuticals Inc (ARWR) in 2026 Q2 at the reported quarter-end price of $81.51 per share.
What's the cost basis of Polen Capital Management's ARWR stake?
The estimated cost basis for Arrowhead Pharmaceuticals Inc (ARWR) stake is around $81.51 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $81.51
Polen Capital Management's historical trades in Arrowhead Pharmaceuticals Inc
1 result
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2026 Q2
|
0.00%
|
6,612
|
$81.51
|
$538,944
|
new
|
+0%
|
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.